← Back
Data updated: Jun 28, 2026
DOMPE FARMACEUTICI
Biotech Pharmaceuticals
DOMPE FARMACEUTICI is a biotechnology company with 1 FDA-approved products.
2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
FDA Novel Drug Designations
(2018) 1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Priority Review 1 Fast Track
See 1 novel approval →
2018 OXERVATE (CENEGERMIN-BKBJ) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track
DOMPE FARMACEUTICI's Key Drugs
DOMPE FARMACEUTICI's core commercial portfolio centers on OXERVATE — its most strategically important drugs approved in the last 15 years.
DOMPE FARMACEUTICI's Recent FDA Approvals
New NDA/BLA approvals for DOMPE FARMACEUTICI over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
DOMPE FARMACEUTICI's Therapeutic Areas
Disease areas where DOMPE FARMACEUTICI has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
DOMPE FARMACEUTICI Pipeline Snapshot
Active clinical trials for DOMPE FARMACEUTICI across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OXERVATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2018-08-22
- Latest
- 2023-10-20
- Applications
- 1